• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by EUDA Health Holdings Limited

    8/6/25 4:05:15 PM ET
    $EUDA
    Medical/Nursing Services
    Health Care
    Get the next $EUDA alert in real time by email
    6-K 1 form6-k.htm 6-K

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    Form 6-K

     

    REPORT OF FOREIGN PRIVATE ISSUER

    PURSUANT TO RULE 13a-16 OR 15d-16

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

     

    For the month of August 2025

     

    Commission File Number: 001-40678

     

    EUDA Health Holdings Limited

    (Exact Name of Registrant as Specified in its Charter)

     

    60 Kaki Bukit Place, #03-01

    Eunos Techpark

    Singapore 415979

    (Address of Principal Executive Offices and Zip Code)

     

    Registrant’s telephone number, including area code: +65-6327-1110

     

    Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F ☒ Form 40-F ☐

     

     

     

     

     

     

    EUDA Health Holdings Limited (“EUDA” or the “Company”) entered into a convertible promissory note purchase agreement dated as of August 1, 2025 (the “Purchase Agreement”) with an institutional investor (the “Purchaser”) to purchase one or more convertible promissory notes (the “Notes”) in an aggregate amount not to exceed $10,000,000. Pursuant to the Purchase Agreement, each Note shall be convertible into newly-issued ordinary shares of the Company, no par value (the “ordinary shares”) at 85% (the “Discount Rate”) of the trading price of the Company’s ordinary shares on the date the Purchaser submits its conversion notice. In the event that the closing bid price of the ordinary shares is less than $2.00 for five (5) consecutive days (the “Early Default”) and the Company has failed to pay the outstanding principal balance of the Notes together with any accrued but unpaid fees within ten (10) business days, Purchaser will have the right to convert the Notes at 70% (the “Early Default Discount Rate”) of the trading price of the Company’s ordinary shares. The Company has agreed to reserve 5,000,000 ordinary shares (the “Shares”) for issuance upon full conversion of all Notes sold under the Purchase Agreement. The Company will file a prospectus supplement relating to the offer and sale of the Notes pursuant to the Purchase Agreement, which will form a part of its Registration Statement on Form F-3 (File No. 333-282723), which was filed with the Securities and Exchange Commission on October 18, 2024 and declared effective on November 4, 2024.

     

    Subject to the terms and conditions of the Purchase Agreement, the Company may deliver to the Purchaser at any time a written request for a Note to be sold to the Purchaser (the “Put Request”), which shall state the amount of such proposed Note and the proposed closing date. Purchaser shall have five (5) business days to decline and/or refuse any Put Request, or purchase such Note at 90% of the principal amount of the Note. Upon the first closing, the Company will issue and sell to the Purchaser a Note in the amount of $1,000,000 (the “First Advance”). The closing of the sale of each subsequent Note will occur on the date to be mutually agreed upon by the Company and the Purchaser.

     

    The foregoing description of the Purchase Agreement and the Note does not purport to be complete and is qualified in its entirety by reference to the full text of the Purchase Agreement and the Note, copies of which are filed as Exhibit 1.1 and 1.2 to this Current Report, respectively and incorporated by reference herein.

     

    This Report on Form 6-K shall not constitute an offer to sell or the solicitation of an offer to buy the ordinary shares (or the Notes) nor shall there be any sale of the ordinary shares (or the Notes) in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.

     

    This Report on Form 6-K is incorporated by reference into the Company’s Registration Statement on Form F-3 (File No. 333-282723) and the prospectus thereof and any prospectus supplements or amendments thereto.

     

    Exhibits

     

    1.1 Convertible Promissory Note Purchase Agreement dated as of August 1, 2025
    1.2 Form of Note

     

     

     

     

    SIGNATURE

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

     

    Dated: August 6, 2025    
       
      EUDA Health Holdings Limited
         
      By: /s/ Vivian Tay
      Name: Vivian Tay
      Title: Interim Chief Financial Officer

     

     

     

    Get the next $EUDA alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $EUDA

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $EUDA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    EUDA Partners with Authorized Distributor of Guangdong Cell Biotech to Offer Stem Cell Therapies to Customers in Singapore and Malaysia

    SINGAPORE, April 24, 2025 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited ("EUDA" or the "Company") (NASDAQ:EUDA), a Singapore-based property management services provider and a leading non-invasive healthcare provider in Singapore and Malaysia, today announced an update to the potential strategic partnership, previously announced in December 2024, with Guangdong Cell Biotech Co. Ltd. ("Guangdong Cell Biotech"). Guangdong Cell Biotech is a prominent player in stem cell therapies and regenerative medicine in China. It develops autologous cell treatments and tailored medicines for various disorders. Instead of the initially contemplated joint venture, the parties have adopted a commercial

    4/24/25 7:00:00 AM ET
    $EUDA
    Medical/Nursing Services
    Health Care

    EUDA Holdings and Guangdong Cell Biotech Explore Potential Strategic Partnership to Advance Biotechnology Innovation

    -        Preliminary Discussions Underway to Establish a Joint Venture SINGAPORE, Dec. 16, 2024 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited ("EUDA" or the "Company") (NASDAQ:EUDA), a Singapore-based health technology company that operates a first-of-its-kind Southeast Asian digital healthcare ecosystem, today announced that it has entered into preliminary discussions with Guangdong Cell Biotech Co. Ltd. ("Guangdong Cell Biotech"), a prominent player in stem cell therapies and regenerative medicine, to form a joint venture. Guangdong Cell Biotech develops autologous cell treatments and tailored medicines for various disorders. This potential collaboration aims to leverage the complem

    12/16/24 5:00:00 PM ET
    $EUDA
    Medical/Nursing Services
    Health Care

    NRx Pharmaceuticals added to Emerging Growth Conference 76 on October 31 and Update to Schedule

    MIAMI, Oct. 31, 2024 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces NRx Pharmaceuticals (NASDAQ:NRXP) will appear on the Emerging Growth Conference today in response to multiple requests and investor demand. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Jonathan Javitt, MD, MPH, Founder and Chairman will be discussing its first steps towards acquisition through its HOPE Therapeutics subsidiary of a national network of interventional psychiatry clinics focused on tr

    10/31/24 7:00:00 AM ET
    $CIA
    $EUDA
    $GOSS
    Life Insurance
    Finance
    Medical/Nursing Services
    Health Care

    $EUDA
    SEC Filings

    View All

    Amendment: SEC Form 6-K/A filed by EUDA Health Holdings Limited

    6-K/A - EUDA Health Holdings Ltd (0001847846) (Filer)

    8/8/25 9:42:06 AM ET
    $EUDA
    Medical/Nursing Services
    Health Care

    SEC Form 424B5 filed by EUDA Health Holdings Limited

    424B5 - EUDA Health Holdings Ltd (0001847846) (Filer)

    8/8/25 9:38:44 AM ET
    $EUDA
    Medical/Nursing Services
    Health Care

    SEC Form 6-K filed by EUDA Health Holdings Limited

    6-K - EUDA Health Holdings Ltd (0001847846) (Filer)

    8/6/25 4:05:15 PM ET
    $EUDA
    Medical/Nursing Services
    Health Care

    $EUDA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by EUDA Health Holdings Limited

    SC 13G - EUDA Health Holdings Ltd (0001847846) (Subject)

    3/27/24 7:35:31 AM ET
    $EUDA
    Medical/Nursing Services
    Health Care